Clinical nuclear medicine continues to advance, metamorphose, and develop new approaches to diagnosis and therapy. In the past year, the most notable advances were in cardiac nuclear medicine, imaging cancer, infection, computer and instrumentation refinements for positron emission tomography (PET) and single photon emission computed tomography (SPECT), refinements in renal functional analysis, and continued clinical documentation of the value of PET imaging.
Food and Drug Administration (FDA) approval of radiopharmaceuticals, marking clinical availability of new agents for all patients in the United States, is always big news in nuclear medicine. In 1994, we saw approval of the indium In 111—labeled somatostatin receptor binding agent, indium In 111 pentetreotide (Octreoscan, Mallinckrodt Inc), for imaging neuroendocrine tumors, technetium Tc 99m bicisate (Neurolite, DuPont Merck Inc) for cerebral perfusion imaging in patients with strokes, and fludeoxyglucose F 18 (formerly known as fluorodeoxyglucose F 18) for imaging metabolic alterations in the brain in patients
Alazraki NP. Nuclear Medicine. JAMA. 1995;273(21):1697-1698. doi:10.1001/jama.1995.03520450067034